SWOG clinical trial number
S1304

A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
RPII Dex + High or Low Dose Carfilzomib for R/R MM
Status Notes
Effective 5/15/16, this study was permanently closed to accrual.
Activated
10/18/2013
Closed
05/15/2016
Participants
NCORP, Members, Medical Oncologists, Pathologists, CTSU, Affiliates

Research committees

Myeloma

Treatment

Dexamethasone Carfilzomib